Rectal cancer T4b V1 TD+ with incomplete response and progressive metastatic disease

2021 ◽  
Author(s):  
Vikas Shah
Keyword(s):  
Rectal Cancer ◽  
Metastatic Disease ◽  
Incomplete Response

Cutaneous Metastases in Patients with Rectal Cancer: A Report of Six Cases

2008 ◽  
Vol 74 (2) ◽  
pp. 138-140 ◽  
Author(s):  
Leo M. Gazoni ◽  
Traci L. Hedrick ◽  
Philip W. Smith ◽  
Charles M. Friel ◽  
Brian R. Swenson ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Cause Of Death ◽  
Metastatic Disease ◽  
Retrospective Review ◽  
Skin Lesions ◽  
Rectal Tumor ◽  
Cutaneous Metastases ◽  
History Of ◽  
Disseminated Disease ◽  
Visceral Malignancy

Cutaneous metastases from rectal cancer are rare manifestations of disseminated disease and uniformly represent dismal survival. A retrospective review of six patients with rectal cancer metastatic to the dermis was performed. The diagnosis of rectal cancer was made concurrently with the diagnosis of the dermal metastases in all six patients. A 100 per cent histopathologic concordance existed between the tissue of the dermal metastases and primary rectal tumor. The progression of systemic metastatic disease was the cause of death in 83.3 per cent of patients (5/6). No patient survived more than 7 months from the time of diagnosis. Recognition of suspicious skin lesions as possible harbingers of undiagnosed visceral malignancy is important in managing patients both with and without a history of previous cancer.

scholarly journals Management of Rectal Cancer and Liver Metastatic Disease: Which Comes First?

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Georgios Tsoulfas ◽  
Manousos-Georgios Pramateftakis
Keyword(s):  
Rectal Cancer ◽  
Metastatic Disease ◽  
Treatment Options ◽  
Surgical Techniques ◽  
Hepatic Metastases ◽  
Multimodality Treatment ◽  
Cancer Management ◽  
Metastatic Lesions ◽  
Synchronous Resection ◽  
Multimodality Approach

In the last few decades there have been significant changes in the approach to rectal cancer management. A multimodality approach and advanced surgical techniques have led to an expansion of the treatment of metastatic disease, with improved survival. Hepatic metastases are present at one point or another in about 50% of patients with colorectal cancer, with surgical resection being the only chance for cure. As the use of multimodality treatment has allowed the tackling of more complicated cases, one of the main questions that remain unanswered is the management of patients with synchronous rectal cancer and hepatic metastatic lesions. The question is one of priority, with all possible options being explored. Specifically, these include the simultaneous rectal cancer and hepatic metastases resection, the rectal cancer followed by chemotherapy and then by the liver resection, and finally the “liver-first” option. This paper will review the three treatment options and attempt to dissect the indications for each. In addition, the role of laparoscopy in the synchronous resection of rectal cancer and hepatic metastases will be reviewed in order to identify future trends.

The role of surgery for locally recurrent and second recurrent rectal cancer with metastatic disease

2020 ◽  
Vol 35 ◽  
pp. 328-335
Author(s):  
Aya Tanaka ◽  
Kay Uehara ◽  
Toshisada Aiba ◽  
Atsushi Ogura ◽  
Toshiki Mukai ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Metastatic Disease ◽  
Recurrent Rectal Cancer ◽  
Locally Recurrent

scholarly journals Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project)

Gut ◽  
2020 ◽  
Vol 70 (1) ◽  
pp. 114-126 ◽  
Author(s):  
Marzieh Araghi ◽  
Melina Arnold ◽  
Mark J Rutherford ◽  
Marianne Grønlie Guren ◽  
Citadel J Cabasag ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Metastatic Disease ◽  
Cancer Survival ◽  
Cancer Registries ◽  
High Income ◽  
Cancer Registration ◽  
Stage At Diagnosis ◽  
Net Survival ◽  
Colon And Rectal Cancer ◽  
Staging Systems

ObjectivesAs part of the International Cancer Benchmarking Partnership (ICBP) SURVMARK-2 project, we provide the most recent estimates of colon and rectal cancer survival in seven high-income countries by age and stage at diagnosis.MethodsData from 386 870 patients diagnosed during 2010–2014 from 19 cancer registries in seven countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the UK) were analysed. 1-year and 5-year net survival from colon and rectal cancer were estimated by stage at diagnosis, age and country,Results(One1-year) and 5-year net survival varied between (77.1% and 87.5%) 59.1% and 70.9% and (84.8% and 90.0%) 61.6% and 70.9% for colon and rectal cancer, respectively. Survival was consistently higher in Australia, Canada and Norway, with smaller proportions of patients with metastatic disease in Canada and Australia. International differences in (1-year) and 5-year survival were most pronounced for regional and distant colon cancer ranging between (86.0% and 94.1%) 62.5% and 77.5% and (40.7% and 56.4%) 8.0% and 17.3%, respectively. Similar patterns were observed for rectal cancer. Stage distribution of colon and rectal cancers by age varied across countries with marked survival differences for patients with metastatic disease and diagnosed at older ages (irrespective of stage).ConclusionsSurvival disparities for colon and rectal cancer across high-income countries are likely explained by earlier diagnosis in some countries and differences in treatment for regional and distant disease, as well as older age at diagnosis. Differences in cancer registration practice and different staging systems across countries may have impacted the comparisons.

scholarly journals Tumor Phosphatidylinositol-3-Kinase Signaling and Development of Metastatic Disease in Locally Advanced Rectal Cancer

PLoS ONE ◽  
2012 ◽  
Vol 7 (11) ◽  
pp. e50806 ◽  
Author(s):  
Anne Hansen Ree ◽  
Annette Torgunrud Kristensen ◽  
Marie Grøn Saelen ◽  
Rik de Wijn ◽  
Hege Edvardsen ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Metastatic Disease ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Kinase Signaling ◽  
Phosphatidylinositol 3 Kinase ◽  
Phosphatidylinositol 3

Transanal Local Excision for Distal Rectal Cancer and Incomplete Response to Neoadjuvant Chemoradiation – Does Baseline Staging Matter?

2014 ◽  
Vol 57 (11) ◽  
pp. 1253-1259 ◽  
Author(s):  
Rodrigo O. Perez ◽  
Angelita Habr-Gama ◽  
Guilherme P. São Julião ◽  
Igor Proscurshim ◽  
Augusto Q. Coelho ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Local Excision ◽  
Neoadjuvant Chemoradiation ◽  
Transanal Local Excision ◽  
Incomplete Response ◽  
Distal Rectal Cancer ◽  
Baseline Staging

Phase II trial evaluating a 12-week regimen of interdigitating FOLFOX chemotherapy plus pelvic chemoradiation for the simultaneous treatment of primary and metastatic rectal cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 3629-3629
Author(s):  
Michael Michael ◽  
Joseph James McKendrick ◽  
Mathias Bressel ◽  
Trevor Leong ◽  
Prasad Cooray ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Treatment Regimen ◽  
Phase Ii ◽  
Metastatic Disease ◽  
Metabolic Response ◽  
Lung Metastases ◽  
Current Phase ◽  
Intensive Chemotherapy ◽  
Radical Radiotherapy ◽  
Folfox Chemotherapy

3629 Background: Current chemotherapy regimens used during chemoradiation (CRT) are adequate for radiosensitization but suboptimal for systemic control. The aim of this study was to assess tolerability, and local/systemic benefits of new regimen delivering intensive chemotherapy and radical radiotherapy in an interdigitating manner. Methods: Phase II prospective study for patients (pts) with untreated simultaneous symptomatic primary and metastatic rectal cancer. The treatment regimen: 12 weeks long. FOLFOX chemotherapy (oxaliplatin 100mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2 bolus, all day 1, and 5FU continuous infusion [CI] 2.4 g/m2/46 hours) was given in weeks 1, 6, and 11. Pelvic CRT: 25.2 Gy in 3 weeks, 1.8 Gy/fr, with concurrent oxaliplatin 85mg/m2 day 1 and 5-FU CI 200mg/m2/day given in weeks 3-5, and 8-10. Pts received, in 12 weeks, 3 courses of FOLFOX and pelvic radiation 50.4 Gy with concurrent oxaliplatin/5-FU. All pt were staged with CT, MRI and FDG-PET before and post-treatment. Results: 26 pts treated. The mean age was 61 years, 69% male. Rectal primary MRI stage was T2 4%, T3 81% and T4 15%. Liver and lung metastases were present in 81%, and 35% of pts, respectively: 38% of patients had more than one site of metastatic disease. 24 pts (92%) completed the 12-week treatment regimen. All pts received the planned radiation dose. 65% of pts received the planned number of oxaliplatin courses with 88% of pts receiving at least 75% of the protocol oxaliplatin dose. In this 12-week period, grade 3 toxicities were neutropenia 23%, diarrhoea 15%, and radiation perineal skin reaction 12%. Only grade 4 toxicity was neutropenia: 15%. PET metabolic response (CR+PR) rate for rectal primary was 96%. Overall PET metabolic response rate for metastatic disease was 60% (CR rate 16%). Conclusions: It is thus feasible to deliver intensive chemotherapy and radical radiotherapy in an interdigitating manner to treat both primary and metastatic rectal cancer simultaneously. High completion and response rates are encouraging. This regimen is the subject of a current phase II neoadjuvant trial for resectable rectal cancer (TROG 09.01).

scholarly journals Rectal Cancer: Asynchronous Metastasis to the Temporal Bone, Temporomandibular Joint and Middle Ear

2020 ◽  
pp. 1-3
Author(s):  
Ali Mahmood ◽  
Aiva Mahmood ◽  
Ali Mahmood ◽  
Nasrullah Manji
Keyword(s):  
Rectal Cancer ◽  
Radiation Therapy ◽  
Diagnostic Imaging ◽  
Temporomandibular Joint ◽  
Temporal Bone ◽  
Middle Ear ◽  
Metastatic Disease ◽  
Advanced Rectal Cancer ◽  
Distant Metastatic Disease ◽  
The Right

Rectal cancer has the potential to metastasize to multiple anatomical sites. The hallmark of treatment presides with sound oncologic surgery, adjunct with chemotherapy and radiation therapy when indicated. The initial presentation determines the management regimen, consisting of physical examination and diagnostic imaging. A 54-year-old female presented with locally advanced rectal cancer. Upon conclusion of neoadjuvant chemotherapy and radiation therapy, she underwent a low anterior resection with total mesorectal excision. Her surgical margins were negative; however, of the 21 lymph nodes retrieved, 11 were positive for cancer. The patient underwent further adjuvant chemotherapy. 2 years, 8 months later, the patient presented to the emergency department with worsening swelling of the right side of the face, with increasing pain, hearing, and visual impairments. Diagnostic imaging revealed a large lesion in the cranial anatomy, invading the temporal bone, temporomandibular joint, sphenoid bone and anterior superior epitympanum of the right middle ear. The patient underwent operative intervention followed by radiation and chemotherapy. Asynchronous metastasis of rectal cancer to the cranium is a rare finding and an invasion into the temporal bone even more scarcely reported. The prognosis for distant metastatic disease is poor because it involves metastatic spread via the lymph channels or vascular system. Patients that have undergone treatment for advanced rectal cancer must be approached with a high index of suspicion for distant metastatic disease, even in the advent of routine negative surveillance

Sign in / Sign up

Export Citation Format

Share Document